November 9, 2023 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

Comments Off on Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

DALLAS, Nov. 9, 2023  -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today ...

Read More
September 13, 2022 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Comments Off on Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Six-month data from Phase 2 STARLIGHT trial expected in H1 2023DALLAS, Sept. 13, 2022  -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal dege ...

Read More
February 7, 2022 in Home Page, Nanoscope Press Release

Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision

Comments Off on Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision

DALLAS, Feb. 7, 2022  -- Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2b cli ...

Read More